Goldman Sachs initiates City Therapeutics stock at Early-Stage Biotech
Goldman Sachs initiated coverage on City Therapeutics (NASDAQ:CTY) with an Early-Stage Biotech rating. The stock trades at $18.67, down 16.7% over six months. CTY develops RNA-interference therapeutics, with three programs targeting Factor XI, Stargardt disease, and myelofibrosis. Goldman estimates peak sales of $15B, $8.1B, and $2B by 2045. Stifel and Jefferies also initiated coverage with Buy ratings and price targets of $34 and $32. The company has partnerships with BLCO and BIIB.
How this was made
The 30-second read
Why it matters
Analyst coverage can generate short‑term buying pressure, but the lack of new clinical data limits long‑term impact.
Market read
Primary relevance is to CTY shareholders; broader market impact is minimal.
What to watch
No recent clinical data released; the estimates are speculative.
Background
The article reports analyst initiation and price targets for City Therapeutics, a clinical‑stage RNAi biotech.
Ticker impact
Goldman Sachs initiated coverage on City Therapeutics with an Early-Stage Biotech rating and provided sales potential estimates for its pipeline.
likely upward pressure as investors price in the new coverage and sales forecasts
Coverage upgrade and high sales estimates are fresh analyst opinions that can attract buying interest.
Market effects
May boost sentiment toward RNA‑interference biotech sector.
Limited to U.S. biotech investors.
Low; relevance confined to niche biotech investors.
Counterpoint
Some investors may view the high sales forecasts as overly optimistic for a pre‑clinical company.
Key entities
- companyCity Therapeutics
Clinical‑stage biotech developing RNA‑interference therapeutics.
- analystGoldman Sachs
Initiated coverage with Early‑Stage Biotech rating.
